CRISPR Therapeutics Financial Ratios
NASDAQ: CRSPHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
53.39+2.95 (+5.85%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CRISPR Therapeutics ratio analysis
CRISPR Therapeutics earned a net margin of -16569.8% in FY 2025, down from -981.5% a year earlier. Return on equity reached -30.3%, meaning CRISPR Therapeutics generated -0.30 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.00, and the current ratio was 13.32.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
CRISPR Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | — | 16.12 | — | 50.80 | — | — | — |
| Price / sales | 1,377.57 | 92.74 | 13.36 | 2,638.06 | 6.29 | 14,043.89 | 11.16 | 464.75 | 22.94 | 48.09 |
| Price / book | 2.52 | 1.79 | 2.63 | 1.69 | 2.40 | 6.07 | 3.44 | 3.70 | 5.01 | 1.07 |
| Operating margin | -18,933.6% | -1,250.4% | -60.0% | -56,190.4% | 40.8% | -49,295.5% | 16.1% | -5,087.8% | -157.7% | -1,319.3% |
| Net margin | -16,569.8% | -981.5% | -41.4% | -54,271.7% | 41.3% | -48,520.9% | 23.1% | -5,281.1% | -166.7% | -448.8% |
| Free cash flow margin | -9,855.5% | -387.7% | -72.7% | -44,484.9% | 50.0% | -35,705.7% | 17.3% | -3,169.4% | -190.0% | -1,082.0% |
| Return on equity (ROE) | -30.3% | -19.0% | -8.2% | -34.7% | 15.7% | -21.0% | 7.1% | -42.1% | -36.4% | -10.0% |
| Return on assets (ROA) | -25.7% | -16.3% | -6.9% | -29.0% | 13.7% | -19.1% | 6.3% | -33.7% | -25.2% | -6.7% |
| Debt / equity | 0.00 | — | — | — | — | — | — | — | — | — |
| Current ratio | 13.32 | 22.07 | 17.54 | 15.30 | 20.17 | 18.21 | 17.29 | 16.81 | 17.12 | 14.56 |
| Revenue growth | -90.6% | -89.9% | 30,885.5% | -99.9% | 127,154.9% | -99.8% | 9,169.8% | -92.4% | 693.9% | 1,990.7% |
| EPS growth | — | — | — | -277.9% | — | -552.1% | — | — | — | — |